Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of G1 Therapeutics Inc (NASDAQ:GTHX) were advancing strongly on above-average volume Tuesday in reaction to a clinical trial readout.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Oncology biotech G1 announced preliminary overall survival, or OS, data from a Phase 2 study of trilaciclib.
Women with metastatic triple-negative breast cancer, or MTNBC, lived significantly longer when administered the investigational compound along with the chemotherapy regimen gemcitabine/carboplatin compared to women receiving chemotherapy alone, according to G1.
Myelopreservation results; the objective response rate, or ORR; progression-free survival, or PFS; and safety data were presented at the San Antonio Breast Cancer Symposium.
Trilaciclib is a myelopreservation agent that protects the bone marrow from damage by chemotherapy and improves patient outcomes.
G1 said topline OS improvements were statistically significant in both trilaciclib arms compared with the chemotherapy-only arm. ORR and PFS data as well as safety data were consistent with previously reported data.
Why It's Important
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
TNBC, according to G1, is the most aggressive type of breast cancer, and mTNBC warrants new treatment options.
"As a company committed to improving the lives, treatment options and outcomes of those living with cancer, we're proud to have a pipeline that now includes three investigational therapies with the potential to become new standards of care for those with breast cancer and benefit women at the earliest stages of their disease," G1 said.
What's Next
G1 intends to submit marketing applications in the U.S. and Europe for myelopreservation in small cell lung cancer in 2020.
It also plans to initiate additional trials to evaluate the myelopreservation and survival benefits of trilaciclib in other tumor types and chemotherapy regimens.
G1 shares were trading higher by 25.57% at $24.80 at the time of publication Tuesday on roughly five times their average volume.
Related Links:
VBI Shares Plunge On Mixed Late-Stage Hepatitis B Vaccine Trial Results
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.